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Background: The causality of overactive bladder syndrome (OAB) is still not fully understood. Several studies indicate a
significant increase of prostaglandin E2 (PGE2) in patients with OAB. However, in order to clarify whether these
compounds can help to objectify the clinical diagnosis, further studies are needed. This prospective study aims to
analyze PGE2 blood levels (sPGE2) in patients with OAB before and after botulinum toxin type A (BoNT-A) therapy.
Methods: Blood samples were obtained from 56 patients (52y, 18–87) with idiopathic OAB. sPGE2 levels were
measured before and 4 weeks after BoNT-A treatment by enzyme linked immunosorbent assay (ELISA). 31 healthy
persons with normal bladder function served as control group (59 y, 21–72). sPGE2 was set in relation to clinical data
and the severity of OAB (wet/dry). The statistical data analysis was performed by using the non-parametric Mann–Whitney
U test and paired t-test.
Results: Significant higher sPGE2 levels were detected in patients with OAB compared to members of the control
group (2750 pg/ml vs. 1674 pg/ml, p < 0.005). Furthermore sPGE2 levels were increased in patients with OAB wet
compared to OAB dry (p <0.01). In 30 patients sPGE2 levels decreased significantly after BoNT-A treatment compared to
baseline (2995 pg/ml vs. 1486 pg/ml, p <0.005). Patients reported an average drug effect of 9 month (0–19); incontinence
pads were needed significantly less frequent (p < 0.05). 3 patients reported no postoperative effect. sPGE2 increased in
two patients compared to initial levels, a single patient showed a remotely decreased sPGE2. Six patients were treated
repeatedly with BoNT-A after showing an sPGE2 re-rise.
Conclusions: sPGE2-level is increased in patients with OAB. We could prove a significant decrease of sPGE2 after
BoNT-A treatment. In this small cohort we could demonstrate a correlation between OAB and sPGE2, especially in the
non-responder group. The use of sPGE2 as a biomarker in diagnostics and follow-up after therapy seems promising. To
what extent sPGE2 can be useful as such needs to be examined prospectively in a larger population.
Keywords: Prostaglandin E2, Overactive bladder, Biomarker, Botulinum toxin type-A* Correspondence: hegele@med.uni-marburg.de
†Equal contributors
Department of Urology and Pediatric Urology, Philipps University Marburg,
Medical School, Marburg, Germany
© 2014 Hegele et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Hegele et al. BMC Urology 2014, 14:85 Page 2 of 7
http://www.biomedcentral.com/1471-2490/14/85Background
The prevalence of idiopathic overactive bladder syn-
drome (OAB) in Europe is estimated at 16% in men and
women [1]. Sixty-eight percent of the women and 60%
of the men are bothered by OAB. It is a serious problem
that negatively affects the quality of life [1,2]. According
to the International Continence Society (ICS), OAB syn-
drome is defined as urinary urgency usually accompan-
ied by frequency and nocturia, with or without urge
incontinence, in the absence of causative infection or
pathological conditions [3]. The reasons for these symp-
toms are still unknown, although already many studies
could uncover compounds and pathways inducing detrusor
contractions and/or detrusor over activity (DO) [4-6].
One of these compounds originates from arachidonic
acid. Prostaglandin E2 (PGE2) is a cytoprotective eicosa-
noid, which is synthesized de novo from the detrusor
muscle or urothelium [7]. It has been shown that PGE2
is increased in carcinogenesis, urinary tract infections
and overactive bladder syndrome [8,9]. The urinary
PGE2 level is significantly increased in OAB and corre-
lates negatively with the maximum cystometric capacity
[10]. In rats, intravesical instillation of PGE2 triggers de-
trusor contractions, but topical application to the ur-
ethra leads to urethral relaxation in rats [11]. Bladder
storage dysfunction and elevated urinary PGE2 levels
have been proven to be enhanced in rats after causing
severe damage to the urothelial barrier [12].
Once a patient is diagnosed with OAB syndrome, life-
style modifications and bladder retraining is suggested.
Pharmacological treatments are needed to improve qual-
ity of life if behavioural training fails. Due to many side
effects the majority of patients discontinue anticholiner-
gic medication [13]. Botulinum toxin (BTX) is a potent
neurotoxin, used to treat different pathologies such as
blepharospasm or spastic torticollis. It attacks one of the
fusion proteins (SNAP-25, syntaxin or synaptobrevin) at
the neuromuscular junction, preventing vesicles from
anchoring to the membrane to release acetylcholine. By
inhibiting acetylcholine release, the toxin interferes with
nerve impulses and causes flaccid paralysis of muscles [14].
BTX type A (BoNT-A) and Onabotulinum toxin are
used to treat neurogenic and/or overactive bladder when
oral anticholinergic medication is not successful or not
tolerated.
Injected into the detrusor muscle, it reduces urgency
and frequency and improves quality of life. Common but
rare side effects are urinary retention and urinary tract
infections [15-17].
Cause and development of OAB are still unknown,
thus further studies are needed to enhance diagnosis of
OAB as well as to identify markers useful for daily clin-
ical routine in verifying the presence of OAB and estab-
lishing treatment monitoring [18-20].The aim of this prospectively designed study was to test
PGE2 in OAB and its changes after BoNT-A therapy.
Methods
Patients
56 patients (48 female, 8 male, mean age of 63 years,
range 18–87) with the typical symptoms of OAB were
enrolled in this study (Group 1).
Overactive bladder specifically is defined as urgency,
with or without urge incontinence, usually with fre-
quency and nocturia [3]. So, all patients in the group of
cases showed each of the symptoms with or without
urge incontinence and have been in treatment accord-
ingly. All patients were non-responder to medical treat-
ment or discontinued anticholinergic therapy due to
severe side effects. None of them underwent BoNT-A
therapy before. The patients underwent a washout either
by getting no more anticholinergic medication before
treatment with BoNT-A, or terminated taking the medi-
cation after application of BoNT-A immediately. So until
the full insertion of the BoNT-A effect after 14 days a
sufficient wash out has taken place in any case.
In addition, none of the patients took medications with
anticholinergic side effects in the investigated group.
31 healthy persons (19 female, 12 male, mean age of
59 years, range 21–72) with normal bladder function
served as control group (Group 2). None of the control
group showed lower urinary tract symptoms in the
14 days before as well on the day of blood collection.
Patient data are summarized in Table 1.
The study was approved by the ethical review commit-
tee of the Philipps University Marburg (AZ 12/11). In-
formed written consent was obtained from all participants
before collecting blood samples for measurement.
Inclusion criteria
Inclusion criteria were urodynamic proved non-neurogenic
overactive bladder with detrusor hyperactivity or hyper-
sensitive low capacity bladder without detrusor hyper-
activity. Detrusorhyperactivity was diagnosed if a pattern
of bladder muscle contraction was observed while uro-
dynamics correlated to the symptoms of overactive blad-
der. On the other side hypersensitive low capacity bladder
without detrusor hyperactivity was defined as the occur-
rence of early urgency before filling to 150 ml and a max-
imum bladder capacitiy less than 350 ml without pattern
of bladder muscle contraction during urodynamics.
All patients with proven neurogenic bladder dysfunc-
tion, chronic pelvic pain, prostate hyperplasia (weight >30
gramm) or bladder outlet obstructions were not included
in this study.
Evaluation included patient history, urine analysis, a
voiding diary and urodynamic studies. Patients were only
included into the control group if patient history and
Table 1 Summarized data of OAB patients (Group 1, Group 1A =wet OAB, Group 1B = dry OAB)) and control group
(Group 2) (f = female, m =male, y = years)
Group Age (y, range) Gender Age (y, range) OAB-Group Gender Age (range)
1 (n = 56) 63 (18–87) 48 f 63.6 (18–87) 1A (n = 44) 40 f/4 m 63 (18–83)
8 m 62 (57–80) 1B (n = 12) 8 f/4 m 64 (40–87)
1 postop (n = 30) 62.1 (40–83) 25 f 59.6 (40–83) 1A (n = 25) 21 f/4 m 63.6 (28–83)
8 m 74.2 (67–80) 1B (n = 5) 4 f/1 m 60.4 (40–67)
2 (n = 31) 59 (21–72) 19 f 62 (28–71)
12 m 56.3 (21–65)
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“International Consultation on Incontinence Question-
naire – Short Form” (ICIQ-SF) and “Kings Health Ques-
tionnaire” (KHQ) scores showed no impaired quality of
life.
All patients were investigated thoroughly and excluded
if they did not meet the criteria.
BoNT-A application
BoNT-A (500 MU Dysport®, Ipsen Pharma, Ettlingen,
Germany) was injected into the detrusor muscle includ-
ing trigone at 20 different locations in general or local
anaesthesia under visual control.
Therapeutic success
Before and 4 weeks after treatment therapeutic success
was assessed on the basis of standardized questionnaires
ICIQ-SF and KHQ. Additionally, all patients were inter-
viewed face-to-face about their individual quality of life,
changes in number of used pads and leakage before and
after BoNT-A treatment.
Sample handling and PGE2 measurement
Before and 4 weeks after BoNT-A treatment, blood
samples were collected in serum-gel-tubes and proc-
essed within 1 h. After centrifugation (3500 rpm for
10 min) serum samples were aliquoted and stored at
−20°C. After defrosting, all samples were diluted (150 μL
of sample +300 μL of Calibrator Diluent). Serum PGE2
(sPGE2) blood levels were measured at room temperature
(18 – 23°C) by a commercialized enzyme linked im-
munosorbent assay (PGE2 Immunoassay, R&D Systems,
Minneapolis, USA). Standard (25,000 pg/mL) was used
to produce a dilution series (2500 pg/mL standard served
as high standard, Calibrator Diluent as zero standard).
The Microplate was prepared with Calibrator Diluent,
zero standard and sample according to manufacturer’s
instructions. After 1 h incubation at room temperature
on a microplate shaker PGE2 Conjugate (50 μl) was
added to each well, a 2 h incubation followed. Each well
was washed with Wash Buffer (400 μl). Remaining Wash
Buffer was aspirated and the plate blotted. Substrate So-
lution was added to each well (200 μl) and incubated for30 minutes at room temperature. Stop Solution (100 μL)
was added to each well. The optical density of each well
was determined within 30 minutes, using a microplate
reader set to 450 nm. Wavelength correction was set to
540 or 570 nm.
Statistical analysis
The statistical data analysis was performed using the
non-parametric Mann–Whitney U test and paired t-test
to compare the different groups and the individual




Baseline data and sPGE2 levels were available for all 56
patients before BoNT-A therapy, hereof 44 with wet
OAB (Group 1A), and 12 with dry OAB (Group 1B).
Median Follow-up was 28 month (range 15–32). For 30
patients control visits 4 weeks after BoNT-A therapy
were realized in order to assess the sPGE2 course in
postoperative samples. In this group median follow-up
was 30 month (range 15–32).
Therapeutic success
OAB symptoms improved. This is reflected in signifi-
cantly decreased urinary frequency (p < 0.01) and signifi-
cant reduction of incontinence episodes (p < 0.05). Pads
were needed significantly less frequent (4 (range 1–18)
vs. 1(range 0–8), p < 0,05).
KHQ indicated a significant improvement of quality of
life in all individual life situations (p < 0.05).
Mean duration of BoNT-A effect was 9 month (range
0–19). 3 patients (2 female, 1 male) reported no ad-
equate effects after BoNT-A treatment and were ranked
as non-responders.
sPGE2 levels before BoNT-A
The average concentration of sPGE2 in Group 1 was sig-
nificantly higher (2749.5 pg/ml, SD 2375.7, range 332–
9422) compared to Group 2 (1674.3 pg/ml SD 873,
range 611–4038, p < 0.005, see Figure 1).
Figure 1 sPGE2 levels in patients with OAB and control group (p < 0.05).
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levels in Group 1A compared to Group 1B (3241 pg/ml
versus 1734 pg/ml, p < 0.01).
sPGE2 levels after BoNT-A
Postoperative sPGE2 levels could be determined in 30
patients of Group 1. Compared to baseline, mean sPGE2
levels significantly decreased 4 weeks after BoNT-A
therapy (2995 pg/ml, SD 2022, range 389–8861 versus
1486 pg/ml, SD 2414, range 201–11286; p <0.005, see
Figure 2).
sPGE2 levels of the different groups are summarized
in Table 2.Figure 2 sPGE2 levels before and 4 weeks after BoNT-A treatment (pDecrease of sPGE2 levels was correlated with the
mean duration of drug effect (9 month). The subgroup
with a shorter drug effect <9 month presented a signifi-
cantly lower sPGE2 decrease (22.2%) compared to pa-
tients with a drug effect >9 month (57.4%, p < 0.05).
Additionally, in 2 of 3 non-responders (66.6%) sPGE2
levels increased after treatment up to 51% compared to
baseline (Pat 1: 1815 pg/ml to 2749 pg/ml (+51.5%)/Pat 2:
1797 pg/ml to 2333 pg/ml (+29.8%)).
Percental decrease/increase of each patient is illus-
trated in Figure 3.
In the study period 6 patients (5 female, 1 male, mean
age of 63.7 years, range 40–76) re-visited our department< 0.005).
Table 2 Summarized pre- and post-BoNT-A median sPGE2-levels of OAB patients (Group 1, Group 1A =wet OAB,
Group 1B = dry OAB)) and control group (Group 2) (f = female, m =male, y = years)
Group sPGE2 pre [pg/ml] Group sPGE2 pre [pg/ml] Group sPGE2 [pg/ml]
1 (n = 56) 2749.5 (332–9422) 1A (n = 44) 3241 (389–9422) 1 (n = 30) pre: 2995 (389–8861)
1B (n = 12) 1734 332–8861) post: 1486 (201–11286)
2 (n = 31) 1674.3 (611–4038)
p-value < 0.005 < 0.01 < 0.005
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the BoNT–A effects wore off after a median time of
8.5 month (range 6–12). Measurements confirmed a re-
rise of sPGE2 in all patients after initial sPGE2 decrease.
After reapplication of BoNT-A a re-decrease of sPGE 2
could be detected.
Discussion
OAB represents a rising health problem massively affect-
ing quality of life. Intravesical BoNT–A administration
has been shown to be a safe and effective therapy for re-
fractory idiopathic OAB. It is a reasonable treatment of
patients impossible to take anticholinergic medication
[15-17,21,22]. To date several studies tried to elucidate
cause and mechanism of OAB, but it is still poorly
understood [4,18,19,23]. Up to now a marker for OAB is
lacking. In general a biomarker should be able to indi-
cate and define both the presence and severity of a dis-
ease as well as progression/relapse and response on
therapy [20]. Prostanoids are inflammatory mediators
induced by mitogens or proinflammatory agents. PGE2
associated physiological responses are found in the
whole human system. Typical prostanoid-induced ac-








































Figure 3 Percentage decrease (−)/increase (+) of sPGE2 in 30 patients
to BoNT-A).neuromodulation (inhibition or release of neurotrans-
mitters, regulation of inflammatory mediation, thermo-
regulation or sleep induction). In the urinary bladder,
PGE2 is released from the urothelium, smooth muscle
[24,25], glial cells and neurons as required [26,27]. Our
results clearly demonstrate the relationship between
PGE2 and OAB reflected in significantly elevated serum
levels of PGE2 in patients suffering from OAB. It is par-
ticularly noticeable that there is a wide range of sPGE2
levels with pronounced inter-individual differences.
These findings are in line with studies trying to find a
urinary marker to differentiate OAB, DO or interstitial
cystitis (IC)/bladder pain syndrome (BPS). Recent stud-
ies showed significantly increased urinary PGE2 in male
and female OAB patients, underlining the important but
still unclear role of PGE2 [5,8,28]. Moreover, our data
detect a correlation of sPGE2 levels with the severity of
OAB reflected by significant higher levels in wet com-
pared to dry OAB. This possible potential to differentiate
between vairous OAB stages reveals PGE2 as promising
for future use as a marker and additional helpful tool for
therapeutic decision in OAB.
For the first time we present data that sPGE2 develop-
ment is influenced by intravesical BoNT-A therapy in2
 after BoNT-A
4 weeks post BoNT-A treatment (red lines: non responders
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4 weeks after BoNT-A application. Furthermore, we de-
tected a correlation between the success of therapy as well
as the degree and duration of decreased sPGE2 levels. A
shorter drug effect (<9 month) was significantly associated
with less sPGE decrease. Non-responders even displayed a
sPGE2 increase or only a slight decrease. A recent study
examined PGE2 urine levels in female OAB patients
treated with anticholinergics and no significant changes of
PGE2 urine levels could be detected after 4 weeks of treat-
ment [28]. These differences in PGE2 detection in urine
and serum may be due to the different methods and body
fluids used and due to the diverging administered thera-
peutic substances. But how far are local urinary levels of
the inflammatory mediators relevant to the inflammatory
process at all? In particular, anticholinergics and BoNT-A
are acting by different receptor mediated signal transduc-
tion pathways affecting Ca++ influx with impact on PGE2
release [29,30]. The regulation and action of prostaglan-
dins in the urinary bladder are still obscure. In addition,
we verified a re-rise of sPGE2 when BoNT-A effects wore
off and OAB relapsed. A limitation of this prospective
single-center examination was the relatively small patient
cohort of 58 OAB-patients. These first promising results,
that show the potential of sPGE2 as a biomarker in OAB,
have to be confirmed in further investigations with a larger
population.
Conclusions
These promising first data are indicate the helpfulness of
sPGE2 in OAB. sPGE2 seems to have the potential as a
biomarker for OAB defining the presence, severity and re-
sponse to therapy and relapse. Future investigations have
to evaluate the relevance of sPGE2 to diagnose and moni-
tor patients with OAB. BoNT-A treated patients could be
monitored using sPGE2 as an early marker to anticipate
decreasing effects of BoNT–A in combination with a void-
ing diary. Regarding the non-responder group, an efficient
monitoring could filter these patients and lead to an alter-
native treatment. To what extent sPGE2 can be useful as
such needs to be examined in further investigations.
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